ANT308

**ANT308** is a synthetic peptide antagonist of vasoactive intestinal polypeptide receptors (VIP-R), specifically targeting **VPAC1** (vasoactive intestinal polypeptide receptor 1) and **VPAC2** (vasoactive intestinal polypeptide receptor 2). It blocks VIP-mediated signaling, which inhibits T cell activation and proliferation in the tumor microenvironment, thereby enhancing anti-tumor immunity. Developed through in silico screening and chemical modifications including N-terminus design, peptide stapling, and PEGylation to improve stability and half-life, ANT308 demonstrates potent T cell activation (e.g., increased CD69, Ki67, granzyme B), reduced regulatory T cells and exhausted T cells, and synergy with anti-PD-1 in preclinical models. It originated from Emory University and is advanced by Cambium Oncology for mutation-agnostic immunotherapy in cancers like pancreatic ductal adenocarcinoma (PDAC) and acute myeloid leukemia (AML).[1][2][4][5][7]

Other names

ANT308 TFAANT-308 TFAANT 308 TFAANT308-PEGANT-308-PEGANT 308-PEGANT308C13C17 stpANT-308C13C17 stpANT 308C13C17 stpANT308-FC3ANT-308-FC3ANT 308-FC3